Introduction
Materials and methods
Results
-
Group A consists of patients which were diagnosed with a neuroendocrine neoplasm and shortly after with CHD succumbing to the disease within a median time of 5 months. Of note, one patient located in the group A circle, was excluded from the analysis as the patient was still alive and the disease is stable at time of reporting.
-
Group B comprised patients which were simultaneously diagnosed with a neuroendocrine tumor and CHD having survived with a median time frame of 4 years.
-
Group C included patients who were diagnosed with CHD within a median time frame of 4 years following NET diagnosis and succumbing to disease shortly after the diagnosis within a median time of 4 months (at time of reporting 1 patient was still alive but receiving palliative care).
All patients, n = 23 | Group Ab, n = 4 | Group B n = 12 | Group C n = 6 | |
---|---|---|---|---|
Sex, n (%) | ||||
Female | 7 (30) | 1 (25) | 4 (33) | 2 (33) |
Male | 16 (70) | 3 (75) | 8 (67) | 4 (67) |
Age at diagnosis, years | ||||
Mean (SD) | 64 (10) | 74 (7) | 65 (10)* | 56 (7)* |
Median (iqr; min; max) | 65 (15; 45; 80) | 76 (9; 64; 80) | 70 (15.5; 49; 78) | 60 (6; 45; 65) |
Death Certified, n (%) | ||||
No | 8 (35) | 0 (0) | 6 (50) | 1 (17) |
Yes | 15 (65) | 4 (100) | 6 (50) | 5 (83) |
Death tumor-related, n (%) | ||||
Yes | 15 (100) | 4 (100) | 6 (100) | 5 (100) |
Time-to-death after NET diagnosis, monthsa | ||||
Mean (SD) | 15 (21) | 3 (2) | 4 (6) | 47(9) |
Median (iqr; min; max) | 3 (28; 0; 61.4) | 2 (2;1;6) | 0.4 (3;0;20) | 48 (12;28; 62) |
Time-to-death after diagnosis of CHD, monthsa | ||||
Mean (SD) | 24 (25) | 7 (6) | 50 (18)* + | 6 (6) |
Median (iqr; min; max) | 16 (34; 0; 144) | 5 (6;1;16) | 49 (26;30;75) | 4 (2;0;17) |
All patients, n = 23 | Group Aa, n = 4 | Group B n = 12 | Group C n = 6 | |
---|---|---|---|---|
Primary tumor site, n (%) | ||||
Ileum/Jejunum | 12 (52) | 2 (50) | 7 (58) | 3 (50) |
CUP | 8 (35) | 2 (50) | 5 (42) | 2 (33) |
Pancreas | 1 (4) | 0 (0) | 0 (0) | 1 (17) |
Caecum | 1 (4) | 0 (0) | 0 (0) | 0 (0) |
Atypical lung carcinoid | 1 (4) | 0 (0) | 0 (0) | 1 (17) |
Diagnosis, n (%) | ||||
Neuroendocrine carcinoma | 3 (13) | 0 (0) | 1 (8) | 2 (33) |
Neuroendocrine tumor | 19 (82) | 4 (100) | 11 (92) | 3 (50) |
Not known | 1 (5) | 0 (0) | 0 (0) | 1 (17) |
Functional tumor, n (%) | ||||
Yes | 20 (87) | 3 (75) | 10 (83) | 6 (100) |
Not known | 3 (13) | 1 (25) | 2 (17) | 0 (0) |
Type of functional tumor, n (%) | ||||
Carcinoid | 17 (74) | 2 (50) | 8 (67) | 6 (100) |
VIPoma | 1 (4) | 1 (25) | 0 (0) | 0 (0) |
unknown | 5 (22) | 1 (25) | 4 (33) | 0 (0) |
Metastasis, n (%) | ||||
Liver | 23 (100) | 4 (100) | 12 (100) | 6 (100) |
Other site | 21 (91) | 2 (50) | 11 (92) | 6 (100) |
Lymph Nodes | 12 (52) | 0 (0) | 9 (75)* | 5 (83)* |
Lung | 2 (9) | 0 (0) | 1 (8) | 1 (17) |
Bone | 11 (48) | 2 (50) | 4 (33) | 5 (83) |
Peritoneum | 8 (35) | 1 (25) | 5 (42) | 3 (50) |
Other | 8 (35) | 0 (0) | 4 (33) | 3 (50) |
Histology, n (%)b | ||||
G1 | 14 (74) | 2 (50) | 9 (82) | 3 (75) |
G2 | 5 (26) | 2 (50) | 2 (18) | 1 (25) |
All patients, n = 23 | Group Aa, n = 4 | Group B, n = 12 | Group C, n = 6 | |
---|---|---|---|---|
Endocard Fibrosis, n (%) | ||||
Yes | 4 (17) | 1 (25) | 1 (9) | 2 (33) |
No | 14 (61) | 2 (50) | 8 (66) | 3 (50) |
Not known | 5 (22) | 1 (25) | 3 (25) | 1 (17) |
Myocardial Decompensation, n (%) | ||||
Yes | 6 (26) | 0 (0) | 3 (25) | 3 (50) |
No | 14 (61) | 3 (75) | 8 (66) | 2 (33) |
Not known | 3 (13) | 1 (25) | 1 (9) | 1 (17) |
Pulmonary Valve Stenosis, n (%) | ||||
Yes | 6 (26) | 2 (50) | 2 (16) | 2 (33) |
No | 13 (57) | 1 (25) | 7 (58) | 4 (67) |
Not known | 4 (17) | 1 (25) | 3 (25) | 0 (0) |
Pulmonary Valve Insufficiency, n (%) | ||||
Yes | 12 (52) | 3 (75) | 8 (75) | 1 (16) |
No | 8 (35) | 1 (25) | 2 (12) | 4 (66) |
Not known | 3 (13) | 0 (0) | 2 (12) | 1 (16) |
Tricuspid Valve Stenosis, n (%) | ||||
Yes | 12 (52) | 2 (50) | 6 (50) | 4 (67) |
No | 19 (39) | 1 (25) | 5 (41) | 2 (33) |
Not known | 2 (9) | 1 (25) | 1 (9) | 0 (0) |
Tricuspid Valve Insufficiency, n (%) | ||||
Yes | 22 (96) | 4 (100) | 12 (100) | 5 (83) |
No | 1 (4) | 0 (0) | 0 (0) | 1 (17) |
Not known | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
All patients, n = 23 | Group Aa, n = 4 | Group B, n = 12 | Group C, n = 6 | |
---|---|---|---|---|
Therapyb,c | ||||
Somatostatin analogue therapy, n (%) | 22 (96) | 4 (100) | 11 (92) | 6 (100) |
Chemotherapy, n (%) | 5 (22) | 0 (0) | 1 (8) | 4 (67) |
Molecular Therapy, n (%) | 6 (26) | 0 (0) | 4 (33) | 2 (33) |
Ablative Therapy, n (%) | 2 (9) | 0 (0) | 2 (17) | 0 (0) |
Peptide receptor radionuclide therapy | 13 (57) | 1 (25) | 7 (58) | 5 (83) |
Surgery, n (%) | 11 (48) | 1 (25) | 7 (58) | 3 (50) |